J. Safra Sarasin Holding AG Has $1.48 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Key Points

• J. Safra Sarasin Holding AG reduced its shares in Zimmer Biomet Holdings, Inc. by 47.9%, selling 12,075 shares to hold a total of 13,114 shares worth $1,484,000.
• In the last quarter, Envestnet Asset Management increased its holdings by 26.4%, while Keybank National Association boosted its stake by 61.2%, indicating increased interest from institutional investors.
• Zimmer Biomet recently reported earnings of $1.81 EPS, exceeding estimates, and announced a quarterly dividend of $0.24 per share, reflecting a current dividend yield of 1.1%.

J. Safra Sarasin Holding AG lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 47.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,114 shares of the medical equipment provider's stock after selling 12,075 shares during the period. J. Safra Sarasin Holding AG's holdings in Zimmer Biomet were worth $1,484,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. MGO One Seven LLC raised its position in Zimmer Biomet by 5.1% in the fourth quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider's stock worth $238,000 after purchasing an additional 110 shares in the last quarter. Janney Montgomery Scott LLC raised its position in Zimmer Biomet by 0.5% in the first quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider's stock worth $2,903,000 after purchasing an additional 118 shares in the last quarter. Curbstone Financial Management Corp increased its holdings in shares of Zimmer Biomet by 3.4% during the first quarter. Curbstone Financial Management Corp now owns 4,266 shares of the medical equipment provider's stock worth $483,000 after buying an additional 140 shares in the last quarter. Roberts Wealth Advisors LLC increased its holdings in shares of Zimmer Biomet by 0.8% during the first quarter. Roberts Wealth Advisors LLC now owns 18,497 shares of the medical equipment provider's stock worth $2,093,000 after buying an additional 152 shares in the last quarter. Finally, Wesbanco Bank Inc. increased its holdings in shares of Zimmer Biomet by 0.8% during the first quarter. Wesbanco Bank Inc. now owns 20,012 shares of the medical equipment provider's stock worth $2,265,000 after buying an additional 163 shares in the last quarter. Institutional investors own 88.89% of the company's stock.

Insider Buying and Selling

In related news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the transaction, the insider owned 20,424 shares in the company, valued at approximately $1,940,280. This represents a 4.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.70% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on ZBH shares. Robert W. Baird dropped their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Truist Financial set a $101.00 price objective on shares of Zimmer Biomet in a report on Tuesday, May 6th. Roth Capital raised shares of Zimmer Biomet from a "neutral" rating to a "buy" rating and set a $135.00 price objective for the company in a report on Tuesday, July 15th. Wells Fargo & Company dropped their price objective on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Finally, Evercore ISI lowered their price target on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $111.39.

Zimmer Biomet Stock Down 0.5%

NYSE:ZBH traded down $0.49 on Tuesday, hitting $91.91. 1,875,533 shares of the company's stock were exchanged, compared to its average volume of 1,773,928. The company has a market cap of $18.18 billion, a P/E ratio of 20.33, a price-to-earnings-growth ratio of 2.16 and a beta of 0.68. The firm has a 50-day moving average price of $93.16 and a 200-day moving average price of $100.07. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $116.71. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. Zimmer Biomet's revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.94 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, July 31st. Investors of record on Thursday, June 26th were paid a $0.24 dividend. The ex-dividend date was Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet's dividend payout ratio is 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.